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The host central nervous system (CNS) response to infectionwith Trypanosoma brucei (T. b.) gambiense or
T. b. rhodesiense parasites, the causing agent of humanAfrican trypanosomiasis (HAT), is a poorly explored
area. The two parasites are responsible for respectively a chronic and an acute form of HAT. In both cases,
however, the disease progresses from a haemolymphatic ﬁrst stage (S1) to a meningo-encephalitic
second stage (S2) due to the penetration of parasites into the CNS.
In the present study, we investigated and compared the cerebrospinal ﬂuid (CSF) from S2 patients
affected by either T. b. gambiense or T. b. rhodesiense HAT, using a mass spectrometry quantitative
proteomics approach. Gene ontology and pathway analyses on the 222 quantiﬁed human proteins
revealed a predominant activation of the innate immune and the acute phase responses in rhodesiense
HAT patients. These resultswere further conﬁrmed through the veriﬁcation of the over-expression of two
proteins involved in these mechanisms, C-reactive protein (CRP) and orosomucoid 1 (ORM1), in
126 S2 HAT patients suffering from either the chronic or the acute form of HAT. Both proteins were
signiﬁcantly increased (p<0.0001) in the CSF of rhodesiense HAT patients.
These ﬁndings contribute in better understanding the pathophysiological mechanisms of late stage
HAT caused by T. b. gambiense or T. b. rhodesiense and pave the way for further investigations on the
clinical signiﬁcance of CRP and ORM1.
Mass spectrometry data are available via ProteomeXchange (identiﬁer PXD001082).
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).r the terms of the Creative
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Human African trypanosomiasis – HAT or sleeping sickness – is
a parasitic disease endemic in sub-Saharan Africa. The disease is
caused by two subspecies of Trypanosoma brucei (T. b.): T. b.
gambiense and T. b. rhodesiense, which are both transmitted
through the bite of tsetse ﬂies of the genus Glossina [1]. The two
parasites are responsible for two forms of HAT that are
geographically separated and clinically different. T. b. gambiensender the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
2 N. Tiberti et al. / Translational Proteomics 6 (2015) 1–9occurs inWest and Central Africa and causes a chronic form of HAT
corresponding to 98% of all reported cases [2]. T. b. rhodesiense is
found in East and South-East Africa, where it causes an acute
infection [3,4].
Sleeping sickness is characterized by the progression from a
ﬁrst haemolymphatic stage (S1) of infection to a second meningo-
encephalitic stage (S2). The ﬁrst stage is associated to the
proliferation of parasites in the host’s bloodstream and lymphatic
system. If not treated, S1 disease most likely progresses to the
second stage as a consequence of the penetration of the parasite
into the central nervous system (CNS) across the blood-brain
barrier (BBB) [5]. The speed of progression from S1 to S2 differs
according to the infecting parasite: it occurs within weeks after
infection in the case of T. b. rhodesiense, while it can takemonths or
years for T. b. gambiense [6]. Consequently, T. b. gambiense HAT is
considered as a chronic disease, while T. b. rhodesiense is seen as an
acute condition. In both cases, however, early stage patients
present unspeciﬁc clinical symptoms and signs, while late stage
patients are associated to the appearance of neurological disorders,
including sleep disturbances [1]. Neurological manifestations have
been reported to be more marked in the gambiense form [7,8],
while cardiac involvement is considered more important in the
rhodesiense one [1,8–11].
The treatment of the two forms of HATalso differs. Pentamidine
is used to treat gambiense S1 patients, while suramin is used for
rhodesiense S1 patients [12]. S2 patients can all be treated with
melarsoprol, which is however highly toxic. In the case of
gambiense HAT, melarsoprol has been replaced by safer alter-
natives, such as eﬂornithine and the nifurtimox–eﬂornithine
combination therapy (NECT) [13,14]. Despite its toxicity, melarso-
prol remains the ﬁrst line treatment of S2 rhodesiense patients [15].
Regardless of the well-known differences in clinical presenta-
tion between both forms of HAT, to date, the investigation of the
host response to the two sub-species of parasite in clinical
samples has hardly been addressed. A number of studies aiming
to discover diagnostic and staging biomarkers have, directly or
indirectly, compared the concentration of immunoglobulins and
immune-mediators in plasma and/or cerebrospinal ﬂuid (CSF) of
patients suffering either from gambiense or rhodesiense HAT [16–
23]. However, to our knowledge, no study has been performed so
far aiming at comparing biological samples from gambiense and
rhodesiense HAT patients. In the present work, we investigated the
CSF from S2 gambiense and rhodesiense patients using a quantita-
tive proteomics approach in order to highlight differences in their
proteome and to evaluate them in the context of HAT pathophysi-
ology.
2. Material and methods
2.1. Ethical statement
HAT patients investigated in the present study were enrolled in
the Democratic Republic of the Congo (D.R.C.), Angola, Uganda and
Malawi as part of prospective studies already published elsewhere
[16,17,21,24]. The relevant Institutional and National Ethics
Committees of the D.R.C., Uganda, Angola, Malawi and Belgium
approved the respective studies.
CSF control samples were obtained at the University Clinics of
Kinshasa (D.R.C.) from subjects being hospitalized for health
problems other than HAT and needing a lumbar puncture as a
required procedure for their care. The study protocolwas approved
by the Kinshasa School of Public Health Ethical Committee and the
Ministry of Public Health of the D.R.C.
All participants signed a written informed consent and
accepted to be enrolled in the studies. For children, or for patients
whose mental state was altered, a signature from a parent or aguardianwas obtained. All patients had the possibility towithdraw
from the study at any moment.
2.2. Population description
Patients suffering from sleeping sickness were diagnosed
based on the parasitological detection of trypanosomes in blood
and/or in lymph. HAT stage was then determined through
the detection of parasites and the counting of white blood cells
(WBC) in CSF, according to the guidelines of the National
Sleeping Sickness Control Programs of the countries of sample
collection. For the present study, patients were classiﬁed as
stage 1 when no parasite was detected in the CSF and the
number of CSF WBC was 5/mL, while stage 2 patients were
deﬁned by the presence of trypanosomes in the CSF and/or
CSF WBC >5/mL, following WHO guidelines [15]. All CSF
samples here investigated were collected before treatment
administration.
All control patients included in the present study were negative
for the presence of trypanosomes in blood and CSF, and had CSF
WBC count <5 cells/mL. None of these patients presented
neurological disorders and their detailed demographic description
is reported in Supplementary Table S1.
2.2.1. Discovery cohort
CSF samples (n =6) obtained from 6 HAT patients were
investigated using a quantitative mass spectrometry (MS) proteo-
mics approach. Among them, 3 patients suffered from S2 T. b.
gambiense HAT and originated from the D.R.C. [24], and 3 patients
suffered from S2 T. b. rhodesiense and originated from T. b.
rhodesiense endemic regions in Uganda – Serere district (FINDTRYP
study) [17]. The demographic description of the patients is
reported in Supplementary Table S2.
2.2.2. Veriﬁcation cohort
The veriﬁcation cohort comprised n =185 CSF samples obtained
from S1 (n =39) and S2 (n=126) HAT patients affected either by the
gambiense or the rhodesiense form of HAT, and from non-infected
control subjects (n =20) (Table 1).
In addition to CSF, n=29 plasma samples obtained from S2 T. b.
gambiense (n =15) and S2 T. b. rhodesiense patients (n =14) were
investigated as well (Supplementary Table S3). These samples
were obtained from a sub-group of patients also tested for CSF.
A graphical summary of the experimental design – from the
discovery to the veriﬁcation – applied in the present study, is
reported in Fig. 1.
2.3. Proteomics investigation
2.3.1. Sample preparation
For each patient (n =6), 60mL of CSF were reduced with 50mM
tris(2-carboxyethyl)phosphine (TCEP), alkylated with 400mM
iodoacetamide and digested overnight at 37 C with trypsin
(Promega, Madison, WI, USA) after having spiked 0.5mg per
sample of bovine beta-lactoglobulin (Sigma–Aldrich, St. Louis, MO,
USA) as an internal control. Samples were then labelled with the
TMT1 6-plex tagging reagents (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) following manufacturer’s instructions. T. b. gambiense
samples were labelled with the tags TMT-126, TMT-127 and TMT-
128, while T. b. rhodesiense samples were labelled with the tags
TMT-129, TMT-130 and TMT-131. After tagging, samples were
pooled, desalted with C18 Macro Spin Columns (Harvard Appara-
tus, Holliston, MA, USA) and dried under vacuum. The
pooled sample was then fractionated by off-gel electrophoresis
(OGE –Agilent, Santa Clara, CA, USA) into 12 fractions using a linear
Table 1
Veriﬁcation cohort; demographic description of HAT patients and control subjects whose CSF was tested in the present study.
T. b. gambiense T. b. rhodesiense Controls
S1 (n =20) S2 (n =63) S1 (n =19) S2 (n =63) (n =20)
Demography
Sex, F (n)a 11 28 9 28 14
Age, years [mean SD]b 3714.4 32.511.8 32.219.3 37.416.6 35.618
Geographical origin
D.R.C., (n) 20 38 – – 20
Angola, (n) – 25 – – –
Uganda, (n) – – 16 38 –
Malawi, (n) – – 3 25 –
CSF examination
Trypanosome positive, n 0 56 0 58 0d
WBC/mL, median [range] 2.5 [1–5] 208 [11–1521] 3 [2–5] 31 [3–1140]c 0 [0–1]
a Chi-squared test, non signiﬁcant differences.
b Kruskal–Wallis test, non signiﬁcant differences.
c Missing information for one patient.
d Missing information for one patient who, however, was CATT negative in blood.
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fraction was desalted with C18 Micro Spin Columns (Harvard
Apparatus, Holliston, MA, USA), dried under vacuum and analysed
by tandem mass spectrometry [25,26].[(Fig._1)TD$FIG]
Fig. 1. Graphical representation of the experim2.3.2. Mass spectrometry analysis
MS analyseswere performed on an electrospray ionization (ESI)
LTQ Orbitrap (OT) velos from Thermo Electron (San Jose, CA, USA)
equipped with a NanoAcquity system from Waters. Peptides wereental design applied in the present study.
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0.120mm pre-column and separated on a home-made 5mm
100Å Magic C18 AQ (Michrom) 0.75150mm column with a
gravity-pulled emitter. The analytical separation was run for
65min using a gradient of H2O/formic acid (FA) 99.9%/0.1% (solvent
A) and CH3CN/FA 99.9%/0.1% (solvent B), run as follows: 0–1min
95% A and 5% B, then to 65% A and 35% B at 55min, and 20% A and
80% B at 65min at a ﬂow rate of 220nL/min. For MS survey scans,
the OT resolutionwas set to 60,000 and the ion populationwas set
to 5105 with an m/z window from 400 to 2000. A maximum of
3 precursors were selected for both collision-induced dissociation
(CID) in the LTQ and high-energy C-trap dissociation (HCD) with
analysis in the OT. ForMS/MS in the LTQ, the ion populationwas set
to 7000 (isolationwidth of 2m/z) while for MS/MS detection in the
OT, it was set to 210E5 (isolation width of 2.5 m/z), with
resolution of 7500, ﬁrst mass atm/z =100, and maximum injection
time of 750ms. The normalized collision energies were set to 35%
for CID and 60% for HCD [26].
2.3.3. Protein identiﬁcation and quantiﬁcation
Protein identiﬁcation was done using EasyProt platform v2.3
[27]. Peak lists were generated from raw data using ReadW
software. After peak list generation, the CID and HCD spectra were
merged for simultaneous identiﬁcation and quantiﬁcation [26].
Peptide spectral matches were searched against Swiss–Prot/
UniProt database (Version 13 June 2012, 5360489 entries), by
choosing Homo sapiens taxonomy. All other searching parameters
were set as follows: (i) oxidized methionines as variable
modiﬁcations; (ii) carbamidomethylation of cysteines, TMT six-
plex amino-termini and TMT six-plex lysines as ﬁxed modiﬁca-
tions; (iii) trypsin was selected as the digestion enzyme allowing
only 1 missed-cleavage, (iv) only peptides with a minimum of 6
residues were selected for identiﬁcation; (v) the precursor ion
tolerance was set to 10ppm.
A second search against the UniProt/TrEMBL database (Version
11 December 2013, 4904530151 entries), choosing the Trypanoso-
matidae taxonomy (ID5654) was performed, in order to check for
the presence of parasite proteins. All other settings were kept as
reported above.
For all identiﬁed humanproteins, relative protein quantiﬁcation
was obtained with Isobar quantiﬁcation tool (version 1.76) [28]
embedded in EasyProt. Only peptides speciﬁc for a unique entry in
the job were taken into account for protein quantiﬁcation, and a
unique quantiﬁed peptide was considered sufﬁcient to obtain
protein quantiﬁcation. The protein ratio T. b. rhodesiense/T. b.
gambiense was computed according to the tagging design, i.e.
129 +130+131/126+127+128, after isotopic purity correction
(according to the algorithm given by the manufacturer) and Isobar
default normalization [28].
The mass spectrometry data have been deposited tothe
ProteomeXchange Consortium (http://proteomecentral.proteo-
mexchange.org) [29] via the PRIDE partner repository [30] with
the dataset identiﬁer PXD001082.
2.4. Gene ontology and pathway analysis
Signiﬁcant differentially expressed CSF human proteins were
submitted to gene ontology (GO) analysis to evaluate their
association with speciﬁc biological processes (BP) GO terms. The
analysis was performed with bioCompendium, available at http://
biocompendium.embl.de.
The whole list of identiﬁed and quantiﬁed CSF human proteins
was further investigated with Ingenuity1 Pathway Analysis – IPA
(Ingenuity1 Systems, Redwood City, CA, USA, http://www.ingenu-
ity.com) [31–33]. Brieﬂy, a list containing the IDs of each identiﬁed
and quantiﬁed protein, the corresponding fold-change for therhodesiense/gambiense ratio, as well as the quantiﬁcation ratio p-
value and sample p-value generated with Isobar, were uploaded in
the IPA analysis tool.
A “Core Analysis” was then performed to highlight important
biological pathways associated to the dataset. The following
settings were applied: Ingenuity knowledge base (genes + endog-
enous chemicals) was the reference set, both direct and indirect
relationships were included and no ﬁlter at the level of the cut-off
or p-value on experimentally observed data were applied to keep
all the entries for the analysis. Finally, human was selected as the
species.
By using the canonical pathway tool of IPA Ingenuity, the
proteins of the experimental dataset have been displayed within
well-established signalling or metabolic pathways. For each
pathway, the following parameters were calculated: p-value,
indicating the association between a speciﬁc pathway and the
experimental dataset; and ratio, indicating the percentage of genes
in a pathway also found in the experimental dataset. This ratio was
computed by dividing the number of genes belonging to a speciﬁc
pathway found in the experimental data set, by the total number of
genes of that pathway. To highlight those pathways most likely
associated to the dataset, the threshold for the p-value was set to
1E-04.
2.5. Veriﬁcation by immunoassays
The concentration of C-reactive protein (CRP), orosomucoid 1
(ORM1) and complement component 9 (C9) was measured using
commercially available immunoassays on the veriﬁcation cohort
(Table 1). CRP was measured by bead suspension assay (mBSA –
Millipore, Billerica, MA, USA), ORM1wasmeasured by competitive
ELISA and C9 by sandwich ELISA (Abcam, Cambridge, UK). All
samples were tested in simplicate and the assays were performed
following manufacturers’ instructions. The technical performance
of the experiments was validated using commercial (for CRP) or
home-made (for ORM1 and C9) quality controls.
2.6. Statistical analyses
Statistical analyses were performed using IBM SPSS v20.0 (IBM,
NY, USA). All statistical tests were two-tailed and the p-value for
signiﬁcance was set to 0.05. Comparisons between two un-paired
groups were done using the Mann–Whitney U test. Comparisons
between more than two unpaired groups were done with the
Kruskal–Wallis test followed by post-test paired comparisons.
When multiple comparisons were done, the Bonferroni’s correc-
tion was applied, multiplying the p-value by the number of
comparisons performed. Box plot graphswere obtainedwith Aabel
v2.4.2 (Gigawiz Ltd. Co., Tulsa, OK, USA).
3. Results
3.1. Quantitative proteomics analysis
The investigation using quantitative proteomics of 6 CSF
samples from HAT S2 patients (n =3 T. b. gambiense and n =3
T. b. rhodesiense) allowed identifying 239 CSF human proteins with
at least 2 unique peptides and <1% false discovery rate (FDR).
Ninety three percent of the identiﬁed peptides were correctly
tagged with the TMT labels, demonstrating the efﬁcient technical
performance of the experiment. The technical variability among
the 6 tags was evaluated through the relative intensity of the
peptides identifying the bovine beta-lactoglobulin – internal
control – which showed a coefﬁcient of variation (CV) of 17%.
After isobar default normalization and removal of proteins
corresponding to keratins (n =3) and those with multiple entries
Table 3
Top-three pathways found to be signiﬁcantly represented in the experimental
dataset.
Pathway Ratioa p-valueb Moleculesc
Acute phase response
signalling
0.243
(42/173)
1.09E-44 C-reactive protein
Alpha-1-acid glycoprotein 1
Lipopolysaccharide-binding
protein
Inter-alpha-trypsin inhibitor
heavy chain H4
Complement component C9
Alpha-1-acid glycoprotein 2
LXR/RXR activation 0.278
(35/126)
1.05E-39 Alpha-1-acid glycoprotein 1
Lipopolysaccharide-binding
protein
Inter-alpha-trypsin inhibitor
heavy chain H4
Complement component C9
Alpha-1-acid glycoprotein 2
Apolipoprotein B-100
Complement system 0.515 (17/
33)
3.05E-25 Complement component C9
For each pathway, the complete list of identiﬁed proteins is available in
Supplementary Table S4.
a Proportion of genes of the dataset belonging to the pathway/total number of
genes of the pathway.
b Association between the pathway and the experimental dataset.
c Signiﬁcantly differentially expressed proteins of the dataset involved in the
pathway.
Table 2
List of proteins quantiﬁed as signiﬁcantly differentially expressed with Isobar quantiﬁcation tool between rhodesiense and gambiense S2 CSF. Only proteins identiﬁed with at
least 2 unique peptides and 1% FDR were considered for quantiﬁcation.
# AC Protein Gene Peptide count Spectral count Ratioa p-value ratiob p-value samplec
1 P06311 Ig kappa chain VIII region IARC/BL41 na 2 2 0.69 0.007 0.002
2 O00584 Ribonuclease T2 RNASE T2 3 3 0.69 0.006 0.019
3 Q9NPR2 Semaphorin-4B SEMA4B 2 2 0.72 0.048 0.017
4 P04114 Apolipoprotein B-100 APOB 4 5 1.36 0.041 0.045
5 P19652 Alpha-1-acid glycoprotein 2 ORM2 5 10 1.49 0.005 0.017
6 Q03591 Complement factor H-related protein 1 CFHR1 1 1 1.52 0.023 0.036
7 P02748 Complement component C9 C9 8 10 1.78 0.006 0.003
8 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 10 18 1.80 0.005 0.026
9 P18428 Lipopolysaccharide-binding protein LBP 2 2 2.31 0.046 0.000
10 P02763 Alpha-1-acid glycoprotein 1 ORM1 6 28 2.69 0.001 0.000
11 P02741 C-reactive protein CRP 3 5 9.30 0.001 0.000
Only proteins having both p-values<0.05 were considered signiﬁcantly differentially expressed. Peptide count and spectral count correspond to the number of peptides and
the number of spectra used for the quantiﬁcation, respectively.
a T. b. rhodesiense/T. b. gambiense [129 +130 +131/126 +127+128].
b p-value ratio: estimator of ratio accuracy relative to the quality of the spectra [28].
c p-value sample: estimator of the biological variability [28].
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the ﬁnal list of quantiﬁed human proteins corresponded to
222 entries (Supplementary MS information).
According to Isobar statistics, 11 proteins resulted to be
signiﬁcantly differentially expressed between rhodesiense and
gambiense samples. Eight of these proteins were over-expressed in
the rhodesiense form of sleeping sickness, while 3 were under-
expressed (Table 2).
No parasite proteinwas identiﬁed (FDR<1%, 2 unique peptides)
when the search for the Trypanosomatidae taxonomy was
performed, probably as a consequence of CSF centrifugation prior
to examination for parasite detection, storage and inclusion in the
specimen bank, as a common laboratory practice. To investigate
parasite proteins, the sediment of the centrifugation should be
analysed.
3.2. Gene ontology and pathway analyses
Among the 11 differentially expressed proteins, 8 were
successfully associated to four BP GO terms. Two of these terms
were signiﬁcantly represented (adjusted p-value<0.05) among the
8 proteins: the acute inﬂammatory response (GO: 0002526) and
the humoral immune response (GO: 0006959) (Supplementary
Fig. S1). Interestingly, the acute inﬂammatory response involved
7 out of the 8 proteins over-expressed in rhodesiense samples
compared to gambiense samples.
To go deeper into the obtained data and to investigate whether
speciﬁc pathwayswere represented in the dataset, an analysiswith
IPA Ingenuity was performed. Among the 222 entries uploaded,
198 were successfully mapped against the Ingenuity knowledge
database and thus used for the subsequent analyses. By applying
the 1E-04 p-value threshold, 13 pathways were selected as
signiﬁcantly represented in our dataset, with themost represented
being the “acute phase response signalling” (p-value =1.09E-44),
the “liver X receptors/retinoid X receptors (LXR/RXR) activation”
(p-value = 1.05E-39) and the “complement system” (p-value =3.05
E-25) (Table 3 and Supplementary Table S4). The ﬁrst of these
pathways, the acute phase response signalling, had 42 of its total
173 genes (24%) represented in our dataset. Of these 42 entries,
30 had a positive fold change (i.e. 1.0) for the rhodesiense/
gambiense ratio and comprised 6 of the signiﬁcantly over-
expressed proteins (Table 3). The second most represented
pathway was the LXR/RXR activation. Among the 34 proteins of
our dataset involved in this pathway, 22 had a positive fold-change,
including 6 signiﬁcantly expressed proteins. Finally, the comple-
ment cascade had 17 out of its 33 components (52%) represented.
Despite the majority of these components had a positive foldchange (14/17), only one – complement component C9 – was
signiﬁcantly differentially expressed between T. b. rhodesiense and
T. b. gambiense, with a rhodesiense/gambiense ratio of 1.78.
CRP, ORM1 and C9 were selected for further veriﬁcation, based
on their TMT ratios as well as on their appearance in the pathways
of interest. CRP showed the highest ratio (rhodesiense/gambiense =
9.30), and was part of the most represented pathway, the acute
phase response signalling (Tables 2 and 3). ORM1 was highly
signiﬁcantly differentially expressed between the two forms of
parasitewith a 2.69 ratio and appeared in the acute phase response
signalling and in the LXR/RXR activation pathways. Finally, the
complement component 9 (C9) had a rhodesiense/gambiense ratio
of 1.78 and appeared in the three most enriched pathways.
3.3. Protein veriﬁcation
To conﬁrm the results obtained from the proteomics discovery
experiment, we compared the concentration of CRP, ORM1 and C9
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S2 HAT patients, measured by immunoassay. CRP and
ORM1 showed a highly signiﬁcant difference (Mann–Whitney U
test, p-value 0.0001), with a rhodesiense/gambiense ratio of
31.59 and 2.79, respectively (Fig. 2 and Supplementary Table S5).
The CSF concentration of C9 showed a lower difference (but still
signiﬁcant) with a p-value =0.044 and a rhodesiense/gambiense
ratio of 1.41, suggesting a less marked accuracy of this molecule in
discriminating between the two forms of HAT in the brain.
Since the investigated patients originated from different
countries (i.e. D.R.C. and Angola for T. b. gambiense; Uganda and
Malawi for T. b. rhodesiense), we evaluated the levels of the
3 molecules with respect to their geographical origin. Neverthe-
less, no statistical difference was observed between samples
collected in countries endemic for the same form of HAT, i.e.
between D.R.C. and Angola, or between Uganda and Malawi
(Supplementary Fig. S2). With this patients’ classiﬁcation, a
signiﬁcantly higher concentration in S2 T. b. rhodesiense compared
to S2 T. b. gambiense CSF was conﬁrmed for CRP, independently
from the country of sample collection. A similar proﬁle was
observed for ORM1 but, interestingly, no signiﬁcant difference was
observed between Congolese and Malawian S2 patients (Supple-
mentary Fig. S2 and Supplementary Table S5). As expected,
C9 showed the less pronounced differences and only Angolan and
Ugandan patients showed different CSF levels of the protein,
further sustaining its limited potential to differentiate the two
forms of sleeping sickness.
To try to put our ﬁndings into the context of HAT progression,
the levels of CRP, ORM1 and C9 were also measured in the CSF of a
small number of S1 patients (T. b. gambiense – n =20; T. b.
rhodesiense – n =19). CSF from control subjects (n =20) were
included as well (Fig. 3).
In gambiense patients, the levels of the 3 molecules were not
different from those measured in controls, except for ORM1, which
was increased in S2 T. b. gambiense compared to controls.
On the contrary, in rhodesiense patients, the concentration of
the 3 molecules measured in the CSF of S2 patients was always
signiﬁcantly higher than in control subjects. Moreover, CRP was
also increased in S1 T. b. rhodesiense compared to controls.
When the levels of the 3 molecules were compared between S1
and S2 patients, the only differences observed were for ORM1 and
C9 for the comparison S1 vs. S2 T. b. rhodesiense; in all other cases
no differencewas observed between S1 and S2 patients infected by
the same sub-species of trypanosome.
Finally, the 3 proteins were also measured in the plasma
samples from a small number of S2 HAT patients (T. b. gambiense
n =15; T. b. rhodesiense n=14). Interestingly, plasma CRP levels[(Fig._2)TD$FIG]
Fig. 2. Box plots of the concentration of CRP, ORM1 and C9measured in the CSF of T. b. gam
and the 90th percentile, circles represent outliers. Mean and median are represented as
been done with the Mann–Whitney U test. *** Corresponds to p-value <0.0001 and * cdiscriminated between gambiense and rhodesiense S2 HAT with a
p-value <0.0001. The two other molecules did not (Fig. 4).
4. Discussion
T. b. gambiense and T. b. rhodesiense HAT have been, for long
time, considered two distinct forms of disease from both clinical
and geographical point of view. To try to contribute in under-
standing the molecular mechanisms characterizing the host
immune response against the two parasites, we compared the
cerebrospinal ﬂuid of patients suffering from S2 HAT caused by
either T. b. gambiense or T. b. rhodesiense parasites.
The global evaluation of CSF human proteins identiﬁed by MS,
showed that pathways associated with the immune response –
acute phase response signalling, LXR/RXR activation and comple-
ment system – were signiﬁcantly enriched in the CSF of HAT late
stage patients, in agreement with the known inﬂammatory
response occurring in the brain of S2 HAT patients. The central
role of the neuro-inﬂammatory response in HAT pathology has, in
fact, already been highlighted [34–39], even if the mechanisms of
CNS invasion by the parasites and of development of neurological
disorders are still not completely understood.
The acute phase response represents the ﬁrst rapid mechanism
of protection against invading microorganisms and acts through
non-speciﬁc processes such as the induction of pro-inﬂammatory
cytokines, the activation of the complement systems and the
opsonization [40]. The increased expression of proteins involved in
this pathway in the CSF of late stage T. b. rhodesiense patients is
thus in agreement with the acute nature of this form of disease
compared to the gambiense one. These results were further
conﬁrmed through the veriﬁcation of CRP and ORM1 on clinical
samples, both resulting to be highly signiﬁcantly differentially
expressed (p<0.0001) between the 2 forms of HAT.
CRP, the most known acute phase protein, is a member of the
pentraxin family and plays an important role in the innate
immunity against a number of stimuli including invading
pathogens [41,42]. Despite non-speciﬁc for a determined infection,
the variations of CRP plasma concentration can be very useful
when considered in the clinical context. Strong increases in plasma
concentration have been observed, among other conditions, during
parasitic diseases, including malaria and leishmaniasis [41].
Considering the CSF compartment, CRP has been widely investi-
gated in the context of bacterial meningitis and it has been
proposed that the presence of gram negative bacteria could
enhance CRP permeability across the blood brain barrier (BBB)
[43]. Despitemainly known of hepatic origin, many cell types have
been suggested to be able to produce CRP, including neuronsbiense (n =63) and T. b. rhodesiense (n =63) S2 patients.Whiskers represent the 10th
a diamond and a solid line on the graphs, respectively. Statistical comparisons have
orresponds to p-value <0.05. T.b.g. = T. b. gambiense; T.b.r. = T. b. rhodesiense.
[(Fig._3)TD$FIG]
Fig. 3. Box plots reporting the concentration of CRP, ORM1 and C9measured in the CSF of control subjects (CTRL, n =20); S1 T. b. gambiense (S1 T.b.g., n =20), S2 T. b. gambiense
(S2 T.b.g., n =63); S1 T. b. rhodesiense (S1 T.b.r., n =19) and S2 T. b. rhodesiense (S2 T.b.r., n =63). Whiskers represent the 10th and the 90th percentile, circles represent outliers.
Mean andmedian are represented as a diamond and a solid line on the graphs, respectively. Statistical comparisons have been done using the Kruskal–Wallis test followed by
paired comparisons (post-test with Bonferroni’s correction). For the three molecules, the Kruskal–Wallis p-value was 0.0001, the p-value of the paired comparisons are
reported in the table.
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CSF of HAT patients is not known and the increased CSF
concentration in S2 rhodesiense could be a consequence of
diffusion from plasma or could be of intrathecal origin.
Interestingly, in a mouse model of obesity, it has been highlighted
that high doses of blood CRP increase BBB permeability [45]. Even
so, the elevated concentration of CRP measured in the CSF of T. b.
rhodesiense patients, both S1 and S2, seems to suggest an early
involvement of this protein in brain inﬂammation. Since it has
been proposed that the passage of the trypanosomes across the
blood-CSF and the BBB could be a multistep process [23,39],[(Fig._4)TD$FIG]
Fig. 4. Box plots of the concentration of CRP, ORM1 and C9 measured in the plasma of
represent the 10th and the 90th percentile, circles represent outliers. Mean and median a
comparisons have been obtained through the Mann–Whitney U test. *** = p-value <0.0deeper investigations will help in determining whether CRP
represents an early response to this invasion, or an enhancer for
parasite brain penetration. Independently from its mechanisms of
production and action, the increased concentration of CRP seems
to be associated to the rhodesiense infection rather than to the
gambiense one, indicating that different immune responses are
elicited by the two trypanosomes, with a predominant involve-
ment of the innate immunity in rhodesiense HAT. These results are
further sustained by the observation of signiﬁcantly increased
concentrations of CRP in the plasma of S2 T. b. rhodesiense
compared to S2 T. b. gambiense.S2 T. b. gambiense (n =15) and S2 T. b. rhodesiense (n =14) HAT patients. Whiskers
re represented as a diamond and a solid line on the graphs, respectively. Statistical
001; ns =non signiﬁcant.
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over-expressed in the CSF of S2 T. b. rhodesiense patients compared
to T. b. gambiense. Even though the speciﬁc function of ORM1 has
not been clearly described yet, this protein seems to act as a
modulator of the inﬂammatory response [46]. ORM1 is mainly
released by hepatocytes, but other cell types such as monocytes,
leukocytes and endothelial cells have shown similar abilities [47].
Among the proposed functions for this protein, two are particularly
interesting in the context of sleeping sickness: its participation in
inﬂammatory signalling between the immune system and the CNS,
and its ability to directly interact with microbial products [46]. In
our study, the CSF concentration of this protein was signiﬁcantly
increased in S2 T. b. rhodesiense patients, while S1 T. b. rhodesiense
CSF showed the same concentration as control subjects. This result
might indicate a different response of CRP and ORM1 to the
inﬂammation. A different time delay of the two proteins has
already been reported, with CRP representing an earlier response
to the onset of inﬂammation compared to ORM1 [48]. Deeper
investigations, also involving experimental models of HAT, are
required to better understand the speciﬁc role of CRP and
ORM1 during HAT infection as well as their mechanisms of
production.
ORM1 is also involved in the LXR/RXR activation, the second
most enriched pathway in our study. LXR – liver X receptors – and
RXR – retinoid X receptors – are transcriptional factors that
participate, as a heterodimer, in the regulation of the expression of
genes involved in cholesterol metabolism and sterol absorption
[49]. LXRs are highly expressed in the intestine, however, their
activity at the BBB level has been demonstrated as well [49,50].
Interestingly, the same pathway was found to be signiﬁcantly
differentially activated in an expression microarray study compar-
ing the response, in animalmodels, to different T. brucei strains: the
LXR/RXR activation pathwaywas found to be predominant in mice
showing more severe pathological effects [51], in agreement with
our ﬁndings.
Another important mechanism associated to the innate
immune response is the activation of the complement cascade
[40]. In our study, the complement cascadewas highly signiﬁcantly
represented in the CSF of S2 HAT patients, but without particular
associationwith one form of the disease, as conﬁrmed by the small
differences of C9 concentration on the veriﬁcation cohort. This
result might suggest that the presence of trypanosomes in the
brain of HAT patients is associated with the activation of the
complement system in the attempt to clear parasites, but without
speciﬁcity for one of the two forms.
Globally, our results indicate that different host responses are
elicited by the two parasites. Similar differences had already been
shownwithin the T. b. rhodesiense subspecies [52]. CRP and ORM1,
the most interesting proteins in our study, did not show any
statistical difference betweenpatients affected by the same formof
HAT but enrolled in different countries. However, it should be
stated that a limited number of samples was tested in the present
study and deeper investigations including a new discovery phase
should be performed to address this question.
The present study has some limitations that should be
taken into account. First, despite the very promising results
obtained for CRP and ORM1, a larger number of clinical samples
should be analysed to better evaluate their clinical interest. These
further investigations should also include a larger number of
plasma samples, both S1 and S2, as they might help in better
understanding the role of CRP and ORM1 in HAT pathophysiology.
Another important aspect that should be underlined is the lack of
clinical information on patients’ neurological conditions.
The correlation between the degree of the neurological involve-
ment and the CSF concentration of CRP and ORM1 could have
helped in better understanding their role in T. b. gambiense andT. b. rhodesiense HAT progression. Finally, important additional
information could be obtained by the investigation of CRP and
ORM1 in CSF samples from patients suffering from other
pathologies endemic in HAT regions, such as HIV, malaria and
meningitis. This kind of analysis would help in better evaluating
CRP and ORM1 potential in terms of disease biomarkers.
In conclusion, in the present study we demonstrated that the
proteomics investigation of rhodesiense and gambiense CSF from
S2 patients, combined with bioinformatics tools and veriﬁcation
strategies, highlighted a prevalent activation of the innate immune
and acute phase responses in the CSF of patients suffering from T. b.
rhodesiense HAT. These results pave the way for further inves-
tigations from both the pathophysiological and the clinical point of
view to determine CRP and ORM1 role in disease progression and
their mechanisms of production. Based on the promising results
reported here, CRP and ORM1 should be further investigated on a
larger number of plasma samples, also including S1 patients, to
extensively evaluate their potential for differentiating between
rhodesiense and gambiense clinical samples. The clinical differenti-
ation of the two forms of disease might become important in the
light of their potential future overlap in Uganda, following the
spread of T. b. rhodesiense infection, due to infected livestock
movement [53]. Since for the moment the two parasites can only
be distinguished by PCR, blood and CSFmarkers, such as CRP,might
ﬁnd an application in the future. Additionally, the validation of CRP
and ORM1 on a larger number of CSF and plasma samples might
reveal other clinical applications, for example for the early
detection of T. b. rhodesiense S2 relapses after treatment.
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